2 - Neutrophils pt. 2 Flashcards
What is swarming?
- collective behaviour exhibited by cells, clime mounds, insects
- relies on positive feedback loops and self regulatory mechanisms
What was found about swarming in 2008?
Noted 2008 for neutrophils in mouse lymph nodes infected with protozoan parasites
Advances in swarming
- Since then, advances in cell imaging have enabled detailed characterization of swarms and their regulation, although control of resolution still largely unknown.
- ‘Pioneer’ neutrophils (NTs) react to stimulus and form small clusters, followed by large (several hundred) migration of other NTs. Swarms compete for NT recruitment
How can neutrophil swarm phenotypes be catergorised?
Neutrophil-swarm phenotypes can be broadly categorized into two forms: transient and persistent swarms.
Transient swarms
- Transient neutrophil swarms form small cell clusters for few minutes before quickly dispersing again
- Neutrophils perform chemotactic migration toward a neutrophil accumulation and migrate out again to join nearby growing swarm centres
- Individual neutrophils often move between competing swarms
Persistent swarms
Persistent swarms show a sustained neutrophil recruitment and form large-cell clusters that can remain stable and persist for hours.
Where are transient swarms found?
- lymph nodes
- lungs
- intestines
Where are persistent swarms found?
- skin
- liver
- spleen
- cornea
What did Kienle find about swarms (2021)?
- NTs secrete attractants, which act through cell surface-expressed G protein-coupled receptors (GPCRs) on adjacent cells
- high chemoattractant concentrations (positive feedback loop) lead to GPCR desensitisation at later stages of the swarm, mediated by GPCR kinases (esp. GRK2)
- desensitisation leads to optimal bacterial detection and containment
Killing mechanisms:
- phagocytosis - pathogens frequently opsonised e.g., by Ab or complement factors
- degranulation - extracellular release of anti-microbial molecules
- NETs
What happens after the killing mechanisms?
- Neutrophils cleared by apoptosis in liver, spleen or bone marrow
- Terminal trafficking – gut, to regulate commensals
- Reverse trafficking – migrate away from site
Reverse trafficking: possible mechanisms (in vitro cell culture)
a. chemoattractants act as chemorepellent at high concentrations
b. reverse transmigration through endothelial cell layers
c. reverse migration in microfluidic chambers depends on which signals a neutrophil encounters
Reverse trafficking: possible mechanisms (in vitro cell culture) described
a. Reverse neutrophil transmigration through endothelial cell monolayers has been reported; reverse transmigrated neutrophils have been characterised by high expression of intercellular adhesion molecule 1 (ICAM1) and low expression of CXC-chemokine receptor 1 (CXCR1)
b. In vitro analysis in microfluidics has identified factors that regulate neutrophil forward and reverse migration
c. The pro-resolving lipid mediator lipoxin A4 (LX4A) induces neutrophil reverse migration whereas zymosan induces neutrophil trapping.
How can neutrophil migration be a drug target?
- Failure to appropriately resolve inflammation - contributes to several inflammatory diseases, e.g. rheumatoid arthritis, pulmonary fibrosis, multiple organ failure
- Neutrophil behaviour - potential target for drug therapies
- Targeting forward migration: inhibit primary signals for neutrophil recruitment or amplification
- Targeting reverse migration: promote neutrophil reverse migration from local sites of damage
Examples of drugs in current clinical trials that specifically target neutrophil migration signals
- SCH 527123 targets CXCR2 - severe asthma, allergen induced asthma, COPD, psoriasis, and colon cancer
- Reparixin targets CXCR1 and CXCR2 - ischaemia-reperfusion injury, lung, pancreatic islet and kidney transplantation, and beast cancer